Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lin Zhang, PhD"'
Autor:
Qi-An Chen, M.B.B.S., Kai Ma, MD, PhD, Lin Zhang, PhD, Wei-Hao Lin, M.B.B.S., Xian-Xian Wu, PhD, Yi-Bo Gao, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100678- (2024)
Introduction: The available approved anticancer drugs for Chinese patients are relatively limited because of China's low participation rate in international clinical trials. Therefore, a focus on approved anti–programmed cell death protein 1 (PD-1)
Externí odkaz:
https://doaj.org/article/d8b2c2314ad34c9797fffab1e8c1e3a5
Publikováno v:
Cancer Control, Vol 29 (2022)
Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by BeiGene. The structure of tislelizumab has been modified to maximally inhibit the binding of PD-1 to programmed death ligand 1 (PD-L1) and
Externí odkaz:
https://doaj.org/article/943ddfab0743476e946031e7e0a5f2c1
Autor:
Yihong Liu MMed, Brian H. May PhD, Anthony Lin Zhang PhD, Xinfeng Guo PhD, Chuanjian Lu PhD, Charlie Changli Xue PhD, Haibo Zhang MD
Publikováno v:
Integrative Cancer Therapies, Vol 18 (2019)
Objectives: To assess the clinical evidence for integrative herbal medicine therapy in the management of chemotherapy-induced peripheral neuropathy (CIPN) and hand-foot syndrome (HFS) resulting from treatments for colorectal cancer (CRC). Design: Ran
Externí odkaz:
https://doaj.org/article/26b59955bd7446e798bb976eb8d64e65
Autor:
Qianqian Guo MD, Anthony Lin Zhang PhD, Charlie Changli Xue PhD, Meaghan E. Coyle PhD, Qianjun Chen PhD
Publikováno v:
Integrative Cancer Therapies, Vol 22 (2023)
Objectives: Chinese herbal medicine (CHM) is widely used in breast cancer, but there is no consensus on the Chinese medicine (CM) syndromes in the different conventional treatment stages (preoperative, postoperative, chemotherapy, radiation therapy a
Externí odkaz:
https://doaj.org/article/c860e4bdaf584ba09e3bdefa99942392